KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Gross Profit: 2018-2025

Historic Gross Profit for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to $64.3 million.

  • Castle Biosciences' Gross Profit fell 8.31% to $64.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.6 million, marking a year-over-year increase of 7.52%. This contributed to the annual value of $271.9 million for FY2024, which is 55.52% up from last year.
  • Per Castle Biosciences' latest filing, its Gross Profit stood at $64.3 million for Q3 2025, which was down 6.16% from $68.6 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Gross Profit peaked at $72.5 million during Q2 2024, and registered a low of $19.0 million during Q3 2021.
  • In the last 3 years, Castle Biosciences' Gross Profit had a median value of $64.3 million in 2025 and averaged $59.2 million.
  • Per our database at Business Quant, Castle Biosciences' Gross Profit soared by 86.33% in 2023 and then decreased by 8.31% in 2025.
  • Quarterly analysis of 5 years shows Castle Biosciences' Gross Profit stood at $20.4 million in 2021, then surged by 40.97% to $28.8 million in 2022, then spiked by 86.33% to $53.7 million in 2023, then surged by 30.60% to $70.1 million in 2024, then fell by 8.31% to $64.3 million in 2025.
  • Its Gross Profit stands at $64.3 million for Q3 2025, versus $68.6 million for Q2 2025 and $71.6 million for Q1 2025.